Takeda joins microbiome-focused biotech partner's $52.6M raise as it pursues more in-house cancer work

A high-profile collaboration with Takeda back in late 2018 bestowed upon Enterome some pharma validation and significant cash — $50 million upfront and another $15 million in R&D cost offset — to fund its microbiome platforms. It also represented the last of such licensing deals you’ll likely see from the French biotech in a while.